| | |

Leukemia Drug for Mesothelioma? Lab Tests Show It’s Possible

ByAlex Strauss
leukemia pill

New data suggests that doctors might have good luck using a leukemia drug to treat pleural mesothelioma.

The drug in question is ponatinib. It sells under the brand name Iclusig. Ponatinib is a pill that inhibits certain enzymes that may lead to mesothelioma tumor growth. 

A study carried out at the University of California showed that the leukemia drug kept mesothelioma cells from growing and spreading in the lab. It could give doctors a new treatment option for patients who do not respond to standard therapies. 

How the Leukemia Drug Works

Ponatinib is a tyrosine kinase inhibitor. Tyrosine kinases are enzymes that interact with certain proteins inside cells. Tyrosine kinases act as on/off switches for many cellular functions. 

In some kinds of cancer, including leukemia and mesothelioma, certain tyrosine kinases are overactive. This means they may be telling cancer cells to grow quickly and migrate to other parts of the body.  Ponatinib blocks this process.

The University of California researchers wanted to know which tyrosine kinases are overactive in mesothelioma cells. Depending on which ones they are, this leukemia drug might be helpful. 

Ponatinib blocks multiple tyrosine kinases. If it can block the ones that are overactive in mesothelioma, it might slow the spread of this virulent cancer. 

Ponatinib Could Be a New Treatment Option

People with malignant pleural mesothelioma do not have many treatment options. Most people start with chemotherapy. Chemotherapy drugs like Alimta aim to kill mesothelioma cells. But chemotherapy does not always work well for mesothelioma treatment. At best, it may extend life by a few months. 

A leukemia drug that blocks growth signaling pathways might get to the heart of the problem. To test the idea, University of California researchers used four different mesothelioma cells lines. All four cell lines showed high levels of two tyrosine kinases. Then, they exposed these cells to ponatinib. 

“Differentially but strongly, ponatinib inhibited the in vitro cell growth and migration of all four malignant pleural mesothelioma lines,” writes lead author Yi-Wei Yang in Experimental Lung Research. Cellular levels of a key tyrosine kinase and the proteins that it manages “were markedly decreased following ponatinib treatment.”

The researchers also applied the leukemia drug to a human mesothelioma tumor in a mouse. It slowed the growth of that tumor and reduced the levels of two important tyrosine kinases. 

“Ponatinib may offer a new therapeutic strategy for malignant pleural mesothelioma patients based on cAbl signaling pathway inhibition,” the team concludes. Unlike some other experimental mesothelioma treatments, ponatinib is already FDA-approved and readily available. 

Other mesothelioma researchers are also exploring tyrosine kinase inhibitors for mesothelioma. In 2016, Canadian researchers found that another leukemia drug called dasatinib (Sprycel) made mesothelioma cells more sensitive to chemotherapy with Alimta.  

Sources:

Yank, YW, et al, “Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma”, October 27, 2020, Experimental Lung Research, Epub ahead of print, https://www.tandfonline.com/doi/abs/10.1080/01902148.2020.1836691?journalCode=ielu20

Monica, V, et al, “Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines”, July 6, 2016, Oncotarget, Epub ahead of print

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…